Studies have also found that combined treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal–epithelial transition in non-small-cell lung carcinoma (5). The gene discussed is MAP2K7; the disease is non-small cell lung carcinoma.